Dr. Pedro Postigo

Dr. Daniela A. Bota is a UCI Health neuro-oncologist who specializes in the treatment of primary and metastatic brain and spinal cord tumors, as well as in the neurological complications of cancers.She earned her medical degree at Carol Davila University of Medicine and Pharmacy in Bucharest, Romania. She completed a residency in neurology at University of Kansas Medical Center in Kansas City, followed by a fellowship in neuro-oncology at Duke University School of Medicine in Durham, N.C.Bota's academic research and clinical practice focus on innovative treatments for brain malignancies. She currently serves as a principal investigator for numerous studies including novel glioblastoma stem-cell targeted chemotherapy agents, cellular immunotherapy studies and wearable devices. She consults for multiple companies involved in developing drugs, cellular therapies and devices for human use. In support of these efforts, Bota’s translational research lab investigates potential therapies for malignant gliomas.She also serves as vice dean for Clinical Research at theUCI School of Medicineand director of theUCI Alpha Stem Cell Clinic. Dr. Bota is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Dr. Tahseen Mozaffar is a board-certified UCI Health neurologist who specialize in neuromuscular disorders, including amyotrophic lateral sclerosis (ALS), myasthenia gravis, inflammatory myopathies, Pompe disease, muscle pathology and all types of muscular dystrophies.He serves as director of the UCI Health ALS & Neuromuscular Center, one of only six Muscular Dystrophy Association-designated centers in California.Mozaffar earned his medical degree at the Aga Khan University in Karachi, Pakistan, where he completed a rotating internship in internal medicine and general surgery. He completed a neurology residency at Barnes-Jewish Hospital in St. Louis, Mo., followed by a fellowship in neuromuscular disorders at Washington University, also in St. Louis.His research focus includes clinical and translational studies of neuromuscular disorders and he is the principal site investigator of more than a dozen clinical trials for myasthenia gravis, immune myopathies and rare and ultra-rare myopathies. He is also the lead UCI investigator for NeuroNEXT, a collaborative national effort to help streamline phase 2 clinical trials for brain disorders that is supported by the National Institute of Neurological Disorders and Stroke (NINDS).As an expert in rare and ultra-rare myopathies, he advises many pharmaceutical companies on clinical trial design and the identification of disease targets. He serves on a Pompe disease advisory board for Amicus Therapeutics and Spark Therapeutics, as well as on the data safety monitoring board for Acceleron and Sarepta Therapeutics. He also is a reviewer with the Emerging Technologies and Training in Neurosciences (ETTN) group for the National Institutes of Health (NIH). He has co-authored more than 175 peer-reviewed publications and has written or co-written more than a dozen book chapters and reviews.Mozaffar, who is also fluent in Hindi and Urdu, sees patients inIrvineandOrange. Dr. Mozaffar is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Pompe Disease, Inclusion Body Myositis, Myositis, Limb-Girdle Muscular Dystrophy, and Thymectomy. Dr. Mozaffar is board certified in American Board Of Psychiatry And Neurology - Neurology.

Irene Litvan is a Neurologist practicing medicine in San Diego, California. She has been practicing medicine for over 47 years. Dr. Litvan is highly rated in 25 conditions, according to our data. Her clinical expertise encompasses Progressive Supranuclear Palsy Atypical, Progressive Supranuclear Palsy, Supranuclear Ophthalmoplegia, Movement Disorders, and Deep Brain Stimulation.